Advertisement

Related Videos

CS Pramesh, MS, FRCS, on Opportunities in India: A Perspective From a Low-Middle Income Country

Varsha Gandhi, PhD, on Ibrutinib

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Advertisement

Advertisement




Jul
06
Today In Oncology
Real-World Heart and Lung Radiation Doses From NHS Breast Radiotherapy Plans
Previously Untreated Advanced NSCLC With High PD-L1 Expressionb PD-1/-L1 Inhibitor Monotherapy or Chemoimmunotherapy
Break Through Cancer and the Lustgarten Foundation Launch New Pancreatic Cancer Initiative
AACR Statement and Call to Action Concerning OMB Proposal
Breast Cancer Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo